The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
February 17, 2025
View Complete Issue         Table of Contents 2019 
Remestemcel-L (Ryoncil) for Graft-Versus-Host Disease (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Remestemcel-L (Ryoncil) for Graft-Versus-Host Disease (online only)
February 17, 2025 (Issue: 1722)
Remestemcel-L (Ryoncil – Mesoblast), an allogeneic bone marrow-derived mesenchymal stromal cell therapy, has been approved by the FDA for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in patients ≥2 months old....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Remestemcel-L (Ryoncil) for Graft-Versus-Host Disease (online only)
Article code: 1722i
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.